Back HIV Prevention HIV Vaccines

HIV Vaccines

May 18 is HIV Vaccine Awareness Day

May 18 is HIV Vaccine Awareness Day, an annual opportunity to call attention to progress in vaccine science and the need for further research on both preventive vaccines that stop new HIV infections and therapeutic vaccines that help the immune system fight existing infection.

alt

Read more:

Novel Entry Inhibitor May Provide Vaccine-like Protection Against HIV

A potential new therapy using a molecule that mimics both the CD4 receptor and the CCR5 co-receptor can stop an HIV-like virus from entering host cells, researchers reported in the February 18 online edition of Nature. Monkeys given gene therapy to produce the eCD4-Ig protein did not become infected after repeated virus exposures, suggesting it may be an effective HIV vaccine alternative as well as a long-acting therapy.

alt

Read more:

HIV R4P: RV144 HIV Vaccine's Effects Were Real -- and Could Be Made to Work Better

Findings from further studies using a reformulation of the only HIV vaccine that has ever worked in a large efficacy trial were presented at the recent HIV Research for Prevention conference (HIVR4P) in Cape Town. They showed evidence of stronger antibody responses, and in-depth analysis of these responses suggests that by further developing a similar vaccine, it may be possible to push the immune system to generate an antibody response to HIV that is sufficiently strong to prevent most infections.

alt

Read more:

Neutralizing Antibodies from Llamas Provide Clues for HIV Vaccine Research

Heavy-chain broadly neutralizing antibodies produced by llamas can neutralize a wide range of circulating HIV virus strains, suggesting that immunization could potentially induce protective antibodies against HIV in humans, according to a report in the December 18 edition of PLoS Pathogens.

alt

Read more:

HIV R4P: The Immunity Project -- An Open-Access T-Cell Vaccine for HIV Infection

Microparticles containing conserved HIV epitopes may be able to prime antigen-presenting dendritic cells, which in turn activate antigen-specific CD8 killer T-cells, offering a potential new approach for developing T-cell-based preventive or therapeutic HIV vaccines, researchers with the open-access Immunity Project reported at the HIV Research for Prevention (HIV R4P) conference last week in Cape Town.

alt

Read more: